Analyst Joseph Schwartz of Leerink Partners maintained a Buy rating on Maze Therapeutics, Inc., retaining the price target of $28.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Schwartz has given his Buy rating due to a combination of factors that highlight Maze Therapeutics, Inc.’s promising future. The company has shown consistent execution in advancing its platform of small-molecule precision medicines, particularly in the renal, cardiovascular, and metabolic disease sectors. The progress of their lead asset, MZE829, in the Phase 2 HORIZON study is noteworthy, as it targets a broad population of patients with APOL1 kidney disease, and initial proof-of-concept data is expected in early 2026.
Additionally, Maze’s second program, MZE782, is advancing well, with initial data from its Phase 1 trial anticipated soon. The company’s financial health is robust, with $264.5 million in cash and cash equivalents, providing a cash runway into the second half of 2027. These factors, combined with the upcoming catalysts and a reiterated price target of $28, underpin Schwartz’s positive outlook and Buy rating for Maze Therapeutics.
In another report released on August 13, H.C. Wainwright also maintained a Buy rating on the stock with a $34.00 price target.
MAZE’s price has also changed moderately for the past six months – from $11.320 to $13.600, which is a 20.14% increase.